Ruxolitinib Versus Best Available Therapy in Patients With Steroid-Refractory Acute Graft-Versus-Host Disease: Final Analysis From the Randomized Phase III REACH2 Trial.
J Clin Oncol · 2025-Dec · PMID 41092247
FFS
FIG 2. Efficacy outcomes (full analysis set). Kaplan-Meier curves for ruxolitinib and BAT for (A) OS, (B) EFS, and (C) FFS. OS was defined as the time from date of random assignment to the date of death due to any cause. EFS was defined as the time from date of random assignment to the date of hematologic disease relapse/progression, graft failure, or death due to any cause. FFS was defined as the time from the date of random assignment to the date of hematologic disease relapse/progression, nonrelapse mortality, or addition of new systemic aGVHD treatment. aGVHD, acute graft-versus-host disease; BAT, best available therapy; EFS, event-free survival; FFS, failure-free survival; HR, hazard ratio; KM, Kaplan-Meier, N, number of patients in a group; n, number of patients with a response; OS, overall survival.
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-23T17:15:06+00:00 |